Skip to main content
Clinical Trials/CTRI/2024/01/061210
CTRI/2024/01/061210Not yet recruitingPhase 2/3

Effectiveness of Ultra high dilution of Chlorpromazinum compared to Individualized Homoeopathic Medicine in reducing Positive symptoms of Schizophrenia - A Single Blind Randomized Controlled Trial

Dr S Sudheer Kumar1 site in 1 country70 target enrollmentStarted: January 11, 2024Last updated:

Trial Snapshot

Phase
Phase 2/3
Status
Not yet recruiting
Sponsor
Enrollment
70
Locations
1
Primary Endpoint
Assessment of reduction in positive symptoms of Schizophrenia using Scale for Assessment of Positive Symptoms, after administration of Homoeopathic Chlorpromazinum and Individualized Homoeopathic Medicine in respective groups.

Study Overview

Brief Summary

The study is a Single Blind Randomized Controlled Trial conducted at the National Homeopathy Research Institute in Mental Health, Kottayam, with a duration of 18 months (12 months enrollment and 6 months follow-up). The primary objective is to compare the effectiveness of homoeopathic Chlorpromazinum with individualized homoeopathic medicine in reducing positive symptoms of schizophrenia. The primary outcome measure is the reduction in positive symptoms assessed by the SAPS (Scale for the Assessment of Positive Symptoms) score. Secondary outcome measures include evaluating the overall symptom reduction with PANSS (Positive and Negative Syndrome Scale) and assessing the effectiveness of homoeopathic medicine in mitigating side effects of antipsychotic medications using the Glasgow Anti-psychotics Side-effect Scale (GASS). Assessments are planned monthly with SAPS, at baseline and study endpoint with PANSS, and every three months with GASS. Monthly follow-ups will be conducted for up to 6 months.

Study Design

Study Type
Interventional
Allocation
Randomized
Masking
Participant Blinded

Eligibility Criteria

Ages
18.00 Year(s) to 65.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • Patients of all genders
  • Ages between 18 and 65 years of age
  • Subjects fulfilling ICD 10 diagnostic criteria of Schizophrenia.
  • Patients under Antipsychotic medication.

Exclusion Criteria

  • Patients with comorbid neuro-psychiatric disorders
  • Patients with serious systemic illness.
  • Pregnant and lactating women.

Outcomes

Primary Outcomes

Assessment of reduction in positive symptoms of Schizophrenia using Scale for Assessment of Positive Symptoms, after administration of Homoeopathic Chlorpromazinum and Individualized Homoeopathic Medicine in respective groups.

Time Frame: Every month from baseline till the conclusion of the study(6th month)

Secondary Outcomes

  • Assessment of overall improvement in the symptoms of Schizophrenia using Positive and Negative Syndrome Scale, after administration of Homoeopathic Chlorpromazinum and Individualized Homoeopathic Medicine in respective groups.(At the baseline and end of the study(6th month))
  • Assessment of reduction in the Side-effects of antipsychotic medications using Glasgow Anti-Psychotics Side-effect Scale after administration of Homoeopathic Chlorpromazinum and Individualized Homoeopathic Medicine in respective groups.(Baseline, at 3rd,and conclusion of the study(6th month))

Investigators

Sponsor
Dr S Sudheer Kumar
Sponsor Class
Other [self]
Responsible Party
Principal Investigator
Principal Investigator

Dr S Sudheer Kumar

National Homoeopathy Research Institute in Mental Health

Study Sites (1)

Loading locations...

Similar Trials